/ /

ModernMedicine Resource Center More Topics

Hepatology Resource Center

Breaking barriers to hepatitis C treatment in the DAA eraTargeted efforts may improve the reach of treatment with direct-acting antiviral agents, according to a new study.
Eight-week drug combo regimen maintains SVR in real-world settingResearchers: Treatment-naïve patients infected with genotype 1 hepatitis C virus can receive shorter regimen.
Systematic review: DAAs provide cost-effective treatment for hepatitis CTimely treatment with direct-acting antivirals is highly cost-effective in virtually all patients infected with HCV.
Underserved HCV patients benefiting from telemedicineAn innovative telemedicine model could substantially reduce the burden of chronic hepatitis C infection.
HCV-related liver disease on the rise in womenThe benefits of HCV treatment will need to extend to all patients in order to stem the rising tide of HCV complications among women and men.
Study: HCV week 4 viral load predicts DAA treatment responseWeek 4 HCV RNA levels have implications for treatment with direct-acting antiviral agents for hepatitis C virus infections.
Researchers: Hepatitis C virus control needs a public health approachA new study suggests a public health approach is necessary to control the spread of hepatitis C virus in urban communities.
DAAs safely treat chronic kidney disease in HCV patientsDirect-acting antiviral therapy with sofosbuvir-based combinations safely and effectively treats HCV infection in patients with early-stage chronic kidney disease.
DAAs improve patient and graft survival after liver transplantLiver transplant outcomes have improved following the introduction of new hepatitis C virus drugs, according to a new study.
Primary care can manage hep C infections with DAAsPrimary care professionals can “substantially expand” HCV treatment in the community, according to new research.